“The published data propose that strategies to alleviate dysfunction such as targeting GCase could be a new therapeutic opportunity for neurodegenerative diseases and lysosomal storage
Gain’s Clinical Candidate GT-02287 Earlier this month, Gain Therapeutics announced the dosing of the first two subjects in a Phase 1 clinical trial of GT-02287,
In an engaging interview, journalist Jane King from LilaMax Media discusses cutting-edge allosteric therapies with Gain Therapeutics’ CEO, Matthias Alder, and their potential in
Designing therapeutics that target cellular proteins can be difficult due to the lack of specific binding sites or the potential for disrupting the normal protein
Parkinson’s Disease is among the most common degenerative brain disorders, affecting millions of people each year in the United States alone. We know that the
On September 30th, 2021 Gain Therapeutics presented at the Cantor Fitzgerald virtual global healthcare conference. Eric Richman, CEO and Manolo Bellotto, GM and President, sat
MJFF 2021 Conference: What is Gain Therapeutics Presenting at the MJFF 2021 Parkinson’s Disease Therapeutics Conference Webinar? This year due to the impact of the
Allosteric Binding Sites: One of the most prevalent issues in drug discovery and development is the difficulty to find novel drug targets. Majority of disease-causing
Gain Therapeutics’ SEE-Tx patented algorithm provides quantitative predictions of druggable binding hot spots based on changes in binding free energy (ΔG). No other company has
MJFF 2021 Conference: The Michael J. Fox. Foundation (MJFF) has held a Parkinson’s Therapeutics Conference annually every fall, starting from 2009. Due to the COVID-19
Gain Therapeutics’ physics-based screening platform is able to identify previously unknown binding pockets on well-validated protein targets by identifying cavities on the surface and in
On April 20th, 2021, Gain Therapeutics announced a multi-target drug discovery and development deal with Zentalis Pharmaceuticals to identify and address novel oncology targets. Gain
At Gain Therapeutics, we are uniquely positioned to capitalize on the AlphaFold project and
extend the scope of our existing technology.
Just last month, AlphaFold launched their Protein Structure Database, containing high-quality predicted structures of every protein in the human body.
For years, the neuroscience industry has been plagued by a high failure rate of drugs in the clinical stages.
“We were thrilled to complete our IPO in March on the Nasdaq Global Market Exchange,” stated Sal Calabrese, Chief Financial Officer of Gain.
Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing
©2022 Gain Therapeutics, Inc